

# CITATION REPORT

List of articles citing

## Hirsutism: implications, etiology, and management

DOI: 10.1016/0002-9378(81)90746-8

American Journal of Obstetrics and Gynecology, 1981,  
140, 815-30.

**Source:** <https://exaly.com/paper-pdf/15197822/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
824	Discussion. <i>American Journal of Obstetrics and Gynecology</i> , <b>1982</b> , 144, 139-140	6.4	
823	Hirsutism and menstrual patterns in women exposed to diethylstilbestrol in utero. <i>American Journal of Obstetrics and Gynecology</i> , <b>1982</b> , 144, 135-40	6.4	26
822	Plasma androgens in women with acne vulgaris. <b>1983</b> , 81, 70-4		118
821	Hirsute women with elevated androgen levels: Psychological characteristics, steroid hormones, and catecholamines. <b>1983</b> , 2, 86-93		18
820	Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. <b>1983</b> , 102, 461-4		29
819	Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency: studies on the natural history of the defect and effect of androgens on gender role. <b>1983</b> , 19, 663-74		79
818	The response of several adrenocortical steroids to the administration of ACTH in hirsute women. <b>1983</b> , 18, 745-7		14
817	Cyproterone acetate and the treatment of hirsutism. <b>1983</b> , 23, 93-8		3
816	The diagnostic value of plasma free testosterone in non-tumorous and tumorous hyperandrogenism. <b>1983</b> , 40, 66-72		10
815	Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. <i>American Journal of Obstetrics and Gynecology</i> , <b>1983</b> , 147, 90-101	6.4	259
814	Endocrine aspects of acne. <b>1983</b> , 30, 495-9		12
813	MALE PSEUDOHERMAPHRODITISM DUE TO 17β-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY: STUDIES ON THE NATURAL HISTORY OF THE DEFECT AND EFFECT OF ANDROGENS ON GENDER ROLE. <b>1983</b> , 663-674		
812	Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. <b>1984</b> , 105, 99-104		29
811	Androgen metabolism by isolated hairs from women with idiopathic hirsutism is usually normal. <b>1984</b> , 82, 62-6		20
810	Serum testosterone concentrations in the evaluation of androgen-producing tumors. <i>American Journal of Obstetrics and Gynecology</i> , <b>1985</b> , 153, 44-9	6.4	57
809	A case of mucinous cystadenocarcinoma of the ovary associated with virilization: pre and post-operative steroid plasma levels. <b>1985</b> , 8, 359-62		8
808	Hirsutism: evaluation and treatment. <b>1985</b> , 12, 215-25		35

807	Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients. <b>1986</b> , 9, 5-9	33
806	Pilosebaceous physiology in relation to hirsutism and acne. <b>1986</b> , 15, 341-62	61
805	Treatment of hirsutism with 5 alpha-reductase inhibitors. <b>1986</b> , 15, 391-405	23
804	The role of testosterone measurement in the investigation of androgen disorders. <b>1986</b> , 23 ( Pt 2), 113-34	32
803	Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. <b>1987</b> , 94, 358-65	12
802	Biomedical versus cultural constructions of abnormality: the case of idiopathic hirsutism in the United States. <b>1988</b> , 12, 219-38	14
801	Clinical markers of androgenicity in acne vulgaris. <b>1988</b> , 119, 723-30	24
800	Treatment with dexamethasone of androgen excess in adolescent patients. <b>1988</b> , 112, 821-6	18
799	Ovarian and peripheral steroid hormones in a case of Sertoli-Leydig cell tumor. <b>1988</b> , 11, 521-5	3
798	Prevalence of late-onset 11 beta-hydroxylase deficiency in hirsute patients. <b>1988</b> , 11, 595-8	22
797	The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. <b>1988</b> , 50, 197-212	305
796	Hyperinsulinemia and Ovarian Hyperandrogenism: Cause and Effect. <b>1988</b> , 17, 685-703	62
795	Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. <b>1989</b> , 320, 559-65	272
794	Skin changes in menopause. <b>1989</b> , 11, 295-304	78
793	Treatment of hirsutism with cimetidine: a prospective randomized controlled trial. <b>1989</b> , 51, 247-50	15
792	Solving the mystery of menstrual dysfunction. <b>1989</b> , 85, 127-32	1
791	The polycystic ovary syndrome: pathogenesis and treatment. <b>1989</b> , 110, 386-99	116
790	Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency. <b>1990</b> , 54, 79-83	16

789	Hyperandrogenism in peripubertal girls. <b>1990</b> , 37, 1333-58	27
788	Incidence of polycystic ovaries in patients with late-onset or persistent acne: hormonal reports. <b>1990</b> , 181, 109-11	18
787	Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients. <b>1990</b> , 4, 225-32	25
786	Hirsutism--beyond the steroidogenic block. <b>1990</b> , 323, 909-11	16
785	Hirsutism. <b>1990</b> , 1, 185-8	2
784	Menstrual dysfunction in hirsute women. <b>1990</b> , 22, 76-8	5
783	Gonadotropin-releasing hormone agonist testing of pituitary-gonadal function. <b>1991</b> , 2, 86-91	1
782	Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women**This work was presented, in part, at the 37th Annual Meeting of the Society for Gynecologic Investigation, St. Louis, Missouri, March 21 to 24, 1990.. <b>1991</b> , 55, 872-876	30
781	Detection of functional ovarian hyperandrogenism in women with androgen excess. <b>1992</b> , 327, 157-62	264
780	Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction. <b>1992</b> , 57, 495-500	38
779	The ratio of androstenedione:11 beta-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. <b>1992</b> , 58, 148-52	37
778	Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome. <b>1992</b> , 7, 1201-4	9
777	The incidence of non-classical 21-hydroxylase deficiency in hirsute adolescent girls. <b>1992</b> , 6, 99-106	15
776	Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. <i>American Journal of Obstetrics and Gynecology</i> , <b>1992</b> , 167, 1807-12	6.4 349
775	Hirsutism. <b>1993</b> , 32, 773-7	11
774	Hirsutism and the effectiveness of spironolactone in its management. <b>1993</b> , 16, 925-32	20
773	Androgen biology as a basis for the diagnosis and treatment of androgenic disorders in women. I. <b>1993</b> , 28, 669-83	35
772	Pathological case of the month. Ovarian stromal hyperthecosis. <b>1993</b> , 147, 591-2	

771	Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. <b>1993</b> , 76, 450-5	24
770	Acne, Hirsutism, and Alopecia in Adolescent Girls: Clinical Expressions of Androgen Excess. <b>1993</b> , 22, 507-532	49
769	Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. <b>1994</b> , 43, 247-55	95
768	Endocrine profile of women with amenorrhea and oligomenorrhea. <b>1994</b> , 45, 247-52	1
767	Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <b>1994</b> , 62, 738-43	36
766	Alterations in androgen conjugate levels in women and men with alopecia. <b>1994</b> , 62, 744-50	21
765	Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia. <b>1995</b> , 4, 179-187	4
764	Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia. <b>1995</b> , 4, 179-187	7
763	Isolated polycystic morphology in ovum donors predicts response to ovarian stimulation. <b>1995</b> , 10, 524-8	23
762	Time-dependent changes in serum 3 alpha-androstane diol glucuronide correlate with hirsutism scores after ovarian suppression. <b>1995</b> , 9, 215-20	6
761	Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. <b>1995</b> , 64, 511-7	59
760	'Exaggerated adrenarche' in children presenting with premature adrenarche. <b>1995</b> , 42, 265-72	43
759	Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. <b>1995</b> , 43, 575-82	37
758	Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. <b>1995</b> , 133, 249-53	44
757	Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. <b>1995</b> , 16, 322-53	369
756	Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women. <i>American Journal of Obstetrics and Gynecology</i> , <b>1995</b> , 172, 1251-6 <sup>6.4</sup>	46
755	Body fat distribution, peripheral indicators of androgenic activity, and blood pressure in women. <b>1996</b> , 6, 181-7	6
754	Value of buserelin testing in the evaluation of hirsute women. <b>1996</b> , 19, 204-9	8

753	Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. <b>1996</b> , 66, 734-40	64
752	The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. <b>1996</b> , 66, 220-2	35
751	The prevalence of non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency among hirsute women in a Turkish population. <b>1996</b> , 45, 381-4	22
750	Hirsutism in the United Arab Emirates: a hospital study. <b>1996</b> , 72, 168-71	13
749	The frequency of late-onset 21-hydroxylase and 11 beta-hydroxylase deficiency in women with polycystic ovary syndrome. <b>1997</b> , 137, 670-4	34
748	Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. <b>1997</b> , 12, 663-6	39
747	A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. <b>1997</b> , 68, 644-7	40
746	Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. <b>1997</b> , 67, 569-72	17
745	Prostate-specific antigen in female serum, a potential new marker of androgen excess. <b>1997</b> , 82, 777-80	56
744	Estrogen dermatitis. <b>1997</b> , 72, 97-103	24
743	How hairy are hirsute women?. <b>1997</b> , 47, 255-60	14
742	Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF). <b>1998</b> , 49, 85-9	22
741	Polycystic ovary syndrome. <b>1998</b> , 27, 877-902, ix	55
740	Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. <b>1998</b> , 21, 348-52	44
739	Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study. <b>1998</b> , 83, 3078-3082	464
738	Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. <b>1998</b> , 69, 66-9	47
737	Role of the ovary in the adrenal androgen excess of hyperandrogenic women. <b>1998</b> , 69, 851-9	36
736	The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. <b>1998</b> , 69, 1075-9	26

735	Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. <b>1998</b> , 70, 274-8	86
734	Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. <b>1998</b> , 83, 3078-82	1193
733	Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. <b>1998</b> , 83, 2317-23	94
732	Hormonal effects of flutamide in young women with polycystic ovary syndrome. <b>1998</b> , 83, 99-102	137
731	High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. <b>1998</b> , 83, 1143-50	98
730	Prevalence of idiopathic hirsutism. <b>1998</b> , 139, 421-3	78
729	Is there a role for leptin in the endocrine and metabolic aberrations of polycystic ovary syndrome?. <b>1998</b> , 13, 535-41	39
728	Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. <b>1998</b> , 95, 14956-60	519
727	Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. <b>1999</b> , 13, 394-400	62
726	Response of the pituitary-adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome. <b>1999</b> , 84, 76-81	16
725	Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. <b>1999</b> , 84, 946-50	21
724	The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. <b>1999</b> , 140, 56-61	20
723	A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. <b>1999</b> , 84, 1304-10	112
722	Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. <i>American Journal of Obstetrics and Gynecology</i> , <b>1999</b> , 181, 596-600	6.4 15
721	Adrenal androgen excess in hyperandrogenism: relation to age and body mass. <b>1999</b> , 71, 671-4	77
720	Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. <b>1999</b> , 71, 1075-8	16
719	Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. <b>1999</b> , 72, 915-25	175
718	Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. <b>1999</b> , 22, 165-8	19

717	21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2000</b> , 183, 1468-74	6.4	128
716	Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. <b>2000</b> , 85, 2488-92		21
715	Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. <b>2000</b> , 85, 81-4		36
714	High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. <b>2000</b> , 85, 4182-7		70
713	Prediction models for insulin resistance in the polycystic ovary syndrome. <b>2000</b> , 15, 2098-102		34
712	Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. <b>2000</b> , 14, 411-6		21
711	Idiopathic hirsutism. <b>2000</b> , 21, 347-62		174
710	Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. <b>2000</b> , 85, 139-46		500
709	A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. <b>2000</b> , 85, 2434-8		906
708	A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women From Spain. <b>2000</b> , 85, 2434-2438		766
707	Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). <b>2000</b> , 14, 38-41		49
706	Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women. <b>2000</b> , 85, 81-84		27
705	Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation. <b>2000</b> , 85, 139-146		380
704	Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. <b>2000</b> , 85, 89-94		129
703	Protocolo diagnóstico del hirsutismo. <b>2000</b> , 8, 1165-1167		
702	A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. <b>2000</b> , 73, 984-7		49
701	Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. <b>2000</b> , 74, 59-62		18
700	Examination of the chin or lower abdomen only for the prediction of hirsutism. <b>2000</b> , 74, 980-3		18



699	Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. <b>2001</b> , 75, 53-8	262
698	Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. <b>2001</b> , 75, 496-500	60
697	Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. <b>2001</b> , 75, 797-802	55
696	Apolipoprotein E alleles in women with polycystic ovary syndrome. <b>2001</b> , 75, 878-80	16
695	Hyperandrogenemia in patients presenting with acne. <b>2001</b> , 75, 889-92	87
694	TNF- $\alpha$ and Hyperandrogenism: A Clinical, Biochemical, and Molecular Genetic Study. <b>2001</b> , 86, 3761-3767	18
693	Polycystic ovaries in Hirsute women with normal menses. <b>2001</b> , 111, 602-6	78
692	Facial and abdominal hair growth in hirsutism: a computerized evaluation. <b>2001</b> , 45, 846-50	19
691	Polycystic ovary syndrome: the new millenium. <b>2001</b> , 184, 87-93	55
690	5 alpha-Reductase inhibitors. <b>2001</b> , 56, 143-80	5
689	Polycystic ovary syndrome. A diagnostic challenge. <b>2001</b> , 28, 1-20	12
688	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders. <b>2001</b> , 7, 120-134	54
687	Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. <b>2001</b> , 19, 257-62	42
686	Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. <b>2001</b> , 56, 25-31	13
685	TNF-alpha and hyperandrogenism: a clinical, biochemical, and molecular genetic study. <b>2001</b> , 86, 3761-7	83
684	Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. <b>2001</b> , 24, 1050-2	111
683	Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. <b>2001</b> , 145, 619-24	50
682	Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. <b>2001</b> , 86, 1626-32	402

681	Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow. <b>2001</b> , 15, 142-9	33
680	Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. <b>2001</b> , 86, 1558-61	26
679	Screening for mutations in the steroidogenic acute regulatory protein and steroidogenic factor-1 genes, and in CYP11A and dosage-sensitive sex reversal-adrenal hypoplasia gene on the X chromosome, gene-1 (DAX-1), in hyperandrogenic hirsute women. <b>2001</b> , 86, 1746-9	17
678	A comparison between the effects of low dose (1 microg) and standard dose (250 microg) ACTH stimulation tests on adrenal P450c17alpha enzyme activity in women with polycystic ovary syndrome. <b>2002</b> , 147, 473-7	12
677	Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. <b>2002</b> , 16, 217-224	24
676	The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. <b>2002</b> , 87, 1134-41	89
675	Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. <b>2002</b> , 87, 2128-33	153
674	Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. <b>2002</b> , 87, 3977-83	78
673	New alternative treatment in hirsutism: bicalutamide 25 mg/day. <b>2002</b> , 16, 63-66	29
672	The plasma homocysteine levels are increased in polycystic ovary syndrome. <b>2002</b> , 53, 157-62	97
671	Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. <b>2002</b> , 77, 581-7	29
670	Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. <b>2002</b> , 77, 674-8	30
669	Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism. <b>2002</b> , 78, 1331-3	14
668	Polycystic ovary syndrome: the new millenium. <b>2002</b> , 186, 219-225	9
667	Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. <b>2003</b> , 46, 625-33	120
666	'Hirsutism': a psychological analysis. <b>2003</b> , 8, 327-45	74
665	Hiperandrogenismo en la mujer diabética: rol de la resistencia insulínica y de la hiperinsulinemia. <b>2003</b> , 50, 363-368	1
664	Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. <b>2003</b> , 79, 942-6	50

663	What are the key features of importance in polycystic ovary syndrome?. <b>2003</b> , 80, 259-61	16
662	Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?. <b>2003</b> , 26, 655-9	31
661	Diagnostic value of prostatic specific antigen in hirsute women. <b>2003</b> , 26, 1198-202	14
660	The evaluation and management of hirsutism. <b>2003</b> , 101, 995-1007	115
659	Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome. <b>2003</b> , 80, 1466-72	29
658	Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?. <b>2003</b> , 27, 115-21	25
657	The effectiveness of the interview for predicting the presence of polycystic ovary syndrome. <b>2003</b> , 17, 449-54	4
656	Polycystic ovary syndrome and cardiovascular disease: a premature association?. <b>2003</b> , 24, 302-12	353
655	Low-dose (2.5 mg/day) finasteride treatment in hirsutism. <b>2003</b> , 17, 419-22	18
654	The diagnosis and management of hirsutism. <b>2003</b> , 21, 285-93	7
653	Diagnostic criteria in polycystic ovary syndrome. <b>2003</b> , 21, 267-75	36
652	Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. <b>2003</b> , 88, 2031-6	184
651	The Evaluation and Management of Hirsutism. <b>2003</b> , 101, 995-1007	61
650	The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. <b>2003</b> , 50, 815-23	24
649	Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. <b>2004</b> , 89, 806-11	146
648	Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. <b>2004</b> , 89, 5558-62	25
647	The investigation of insulin resistance in patients with idiopathic hirsutism. <b>2004</b> , 89, 2741-4	37
646	Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. <b>2004</b> , 62, 278-82	27

645	A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. <b>2004</b> , 150, 351-4		39
644	Androgen excess in women: experience with over 1000 consecutive patients. <b>2004</b> , 89, 453-62		817
643	Hirsutism and acne in polycystic ovary syndrome. <b>2004</b> , 18, 737-54		116
642	The prevalence of androgen excess among patients with minimal unwanted hair growth. <i>American Journal of Obstetrics and Gynecology</i> , <b>2004</b> , 191, 1914-20	6.4	50
641	Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. <b>2004</b> , 19, 115-24		29
640	Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. <b>2004</b> , 89, 2640-6		134
639	Recent advances in the treatment of polycystic ovary syndrome. <b>2004</b> , 13, 1295-305		9
638	Relative safety and efficacy of finasteride for treatment of hirsutism. <b>2004</b> , 38, 1070-3		23
637	Polycystic Ovarian Syndrome. <b>2004</b> , 489-512		1
636	The modern management of hirsutism. <b>2004</b> , 4, 211-220		11
635	Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. <b>2004</b> , 57, 1279-87		105
634	Pathogenesis of polycystic ovary syndrome: what is the role of obesity?. <b>2004</b> , 53, 358-76		62
633	Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. <b>2004</b> , 87, 29-33		30
632	The prevalence and features of the polycystic ovary syndrome in an unselected population. <b>2004</b> , 89, 2745-9		1849
631	Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. <b>2004</b> , 81, 120-5		38
630	Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. <b>2004</b> , 81, 126-31		56
629	A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. <b>2004</b> , 81, 630-7		190
628	The evaluation and treatment of androgen excess. <b>2004</b> , 82 Suppl 1, S173-80		2

627	Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome. <b>2004</b> , 82, 1697-9	17
626	Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. <b>2005</b> , 52, 299-308	63
625	Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). <b>2005</b> , 62, 644-9	173
624	Hidradenitis suppurativa: evidence for an endocrine abnormality. <b>1985</b> , 72, 1002-4	44
623	Endocrine basis for the clinical presentation of hidradenitis suppurativa. <b>1988</b> , 75, 972-5	79
622	Ovarian function during puberty in girls with type 1 diabetes mellitus: response to leuprolide. <b>2005</b> , 90, 3939-45	44
621	Preserved insulin sensitivity and {beta}-cell activity, but decreased glucose effectiveness in normal-weight women with the polycystic ovary syndrome. <b>2005</b> , 90, 3381-6	28
620	A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. <b>2005</b> , 20, 2879-86	95
619	Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. <b>2005</b> , 90, 6014-21	161
618	Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. <b>2005</b> , 18, 761-8	60
617	The evaluation and treatment of hirsute women. <b>2005</b> , 1, 429-35	3
616	Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. <b>2005</b> , 90, 729-33	105
615	Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. <b>2005</b> , 20, 3184-91	57
614	Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. <b>2005</b> , 83, 1454-60	393
613	Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. <b>2005</b> , 83, 1717-23	187
612	The hirsutism scoring system should be population specific. <b>2005</b> , 84, 778-80	19
611	Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. <b>2005</b> , 84, 1693-7	16
610	Polycystic ovary syndrome in adolescence. <b>2005</b> , 34, 677-705, x	83

609	Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. <b>2005</b> , 90, 2571-9	107
608	Tratamientos coadyuvantes del hirsutismo. <b>2005</b> , 52, 365-373	
607	Clinical practice. Hirsutism. <b>2005</b> , 353, 2578-88	224
606	The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. <b>2005</b> , 90, 6364-9	291
605	Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. <b>2005</b> , 90, 4068-74	211
604	Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. <b>2006</b> , 91, 3451-6	113
603	Mild androgen phenotypes. <b>2006</b> , 20, 207-20	23
602	Diagnosis of hyperandrogenism: clinical criteria. <b>2006</b> , 20, 167-76	70
601	The PON1-108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. <b>2006</b> , 21, 3157-61	15
600	Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. <b>2006</b> , 85, 214-9	65
599	Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. <b>2006</b> , 85, 436-40	66
598	Role of diet in the treatment of polycystic ovary syndrome. <b>2006</b> , 85, 679-88	105
597	Selecting controls is not selecting "normals": design and analysis issues for studying the etiology of polycystic ovary syndrome. <b>2006</b> , 86, 1-12	54
596	Family size in women with polycystic ovary syndrome. <b>2006</b> , 85, 1837-9	12
595	Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. <b>2006</b> , 86, 405-10	20
594	The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. <b>2006</b> , 86, 914-33	85
593	Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. <b>2006</b> , 86, 1688-93	28
592	The evaluation and treatment of androgen excess. <b>2006</b> , 86, S241-7	39

591	Dermatology of androgen-related disorders. <b>2006</b> , 24, 289-98	55
590	Polycystic ovary syndrome and its differential diagnosis. <b>2006</b> , 61, 125-35	35
589	Female pattern hair loss, sebum excretion and the end-organ response to androgens. <b>2006</b> , 154, 85-9	23
588	Women with polycystic ovary syndrome are sensitive to the TNF-alpha-lowering effect of glucose-induced hyperinsulinaemia. <b>2006</b> , 36, 883-9	10
587	Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. <b>2006</b> , 91, 4085-91	69
586	Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. <b>2006</b> , 114, 182-7	18
585	Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. <b>2006</b> , 91, 2250-6	81
584	Metformin treatment is effective in obese teenage girls with PCOS. <b>2006</b> , 21, 2252-6	78
583	Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. <b>2006</b> , 91, 1345-50	145
582	Investigation of adrenal functions in patients with idiopathic hyperandrogenemia. <b>2006</b> , 155, 307-11	7
581	Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. <b>2006</b> , 166, 2081-6	220
580	Sleep Disorders in Women. <b>2006</b> ,	3
579	Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. <b>2006</b> , 29, 372-8	19
578	Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. <b>2006</b> , 91, 2-6	283
577	Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. <b>2007</b> , 20, 41-51	34
576	Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. <b>2007</b> , 22, 3197-203	108
575	Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. <b>2007</b> , 92, 2500-5	236
574	Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. <b>2007</b> , 92, 4742-6	41

573	Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. <b>2007</b> , 92, 328-37	126
572	Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. <b>2007</b> , 68, 209-17	52
571	Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS. <b>2007</b> , 115, 380-6	25
570	Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. <b>2007</b> , 92, 2453-61	89
569	Endocrinological markers for assessment of hyperandrogenemia in hirsute women. <b>2007</b> , 67, 35-41	16
568	The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. <b>2007</b> , 23, 325-31	32
567	Diagnosis of polycystic ovary syndrome. <b>2007</b> , 50, 168-77	66
566	Serum levels of 3alpha-androstenediol glucuronide in young women with polycystic ovary syndrome, idiopathic hirsutism and in normal subjects. <b>2007</b> , 132, 88-92	3
565	Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. <b>2007</b> , 87, 862-9	36
564	Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. <b>2007</b> , 87, 1473-6	17
563	Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome. <b>2007</b> , 87, 1377-82	8
562	ACTH stimulation test in lean polycystic ovary syndrome patients with insulin resistance. <b>2007</b> , 88, 670-4	1
561	Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. <b>2007</b> , 76, 342-7	22
560	Treatment of the Obese Patient. <b>2007</b> ,	3
559	Dermatologic manifestations of polycystic ovary syndrome. <b>2007</b> , 8, 201-19	53
558	Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. <b>2007</b> , 23, 38-44	41
557	Polycystic ovary syndrome: a common reproductive and metabolic disorder necessitating early recognition and treatment. <b>2007</b> , 34, 761-89, vi	14
556	Color Doppler sonographic analysis of uterine and ovarian artery blood flow in women with polycystic ovary syndrome. <b>2007</b> , 35, 305-13	34



555	Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?. <b>2007</b> , 33, 166-73		15
554	The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. <b>2007</b> , 67, 904-8		47
553	Hirsutism. <b>2008</b> , 62, 433-43		32
552	Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. <i>American Journal of Obstetrics and Gynecology</i> , <b>2007</b> , 196, 398.e1-5; discussion 398.e5-6 <sup>6.4</sup>	6.4	12
551	The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. <i>American Journal of Obstetrics and Gynecology</i> , <b>2007</b> , 196, 402.e1-10; discussion 402.e10-1	6.4	76
550	Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. <b>2008</b> , 25, 321-8		15
549	Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women. <b>2008</b> , 32, 700-3		34
548	Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 198, 670.e1-7; discussion 670.e7-10	6.4	70
547	Medical treatment of hirsutism. <b>2008</b> , 21, 329-39		51
546	Congenital adrenal hyperplasia. <b>2008</b> , 21, 340-53		15
545	What every physician should know about polycystic ovary syndrome. <b>2008</b> , 21, 354-61		29
544	The clinical evaluation of hirsutism. <b>2008</b> , 21, 376-91		40
543	Evaluation of safety and efficacy of variable pulsed light in the treatment of unwanted hair in 77 volunteers. <b>2008</b> , 22, 311-5		13
542	Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. <b>2008</b> , 93, 1105-20		263
541	Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. <b>2008</b> , 43, 115-24		13
540	Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute women. <b>2008</b> , 73, 41-6		11
539	Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. <b>2008</b> , 90, 2310-7		23
538	Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. <b>2008</b> , 22, 177-84		94

537	Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. <b>2008</b> , 103, 44-9	19
536	Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. <b>2008</b> , 24, 392-8	33
535	Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. <b>2008</b> , 24, 199-206	28
534	Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. <b>2008</b> , 23, 1594-601	29
533	Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. <b>2008</b> , 159, 225-32	12
532	Assessment, diagnosis and treatment of a patient with hirsutism. <b>2008</b> , 4, 294-300	8
531	Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. <b>2008</b> , 23, 1214-9	22
530	Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. <b>2008</b> , 24, 718-23	25
529	Exercise and body image distress in overweight and obese women with polycystic ovary syndrome: a pilot investigation. <b>2008</b> , 24, 555-61	29
528	Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. <b>2008</b> , 23, 651-61	85
527	Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. <b>2008</b> , 23, 1924-31	84
526	Psychological implications of infertility in women with polycystic ovary syndrome. <b>2008</b> , 23, 2064-71	73
525	The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. <b>2008</b> , 36, 1188-96	53
524	FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. <b>2008</b> , 23, 2842-9	21
523	Testosterone and bioavailable testosterone help to distinguish between mild Cushing's syndrome and polycystic ovarian syndrome. <b>2008</b> , 40, 813-8	14
522	3alpha-Hydroxysteroid dehydrogenase type III deficiency: a novel mechanism for hirsutism. <b>2008</b> , 93, 1298-303	7
521	A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. <b>2008</b> , 93, 527-33	127
520	European Consensus on the evaluation of women presenting with excessive hair growth. <b>2009</b> , 19, 597-602	20

519	Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. <b>2009</b> , 15, 477-88	232
518	Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. <b>2009</b> , 161, 737-45	41
517	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome. <b>2009</b> , 24, 1184-90	8
516	Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. <b>2009</b> , 88, 32-45	69
515	Rationelle Diagnostik in der gynkologischen Endokrinologie und Reproduktionsmedizin Teil 1: Physiologie und Symptomabklrung. <b>2009</b> , 69, R43-R65	
514	Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. <b>2009</b> , 94, 3282-8	57
513	Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. <b>2009</b> , 94, 1923-30	181
512	The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism. <b>2009</b> , 117, 205-8	4
511	Predictors of pregnancy in women with polycystic ovary syndrome. <b>2009</b> , 94, 3458-66	51
510	Management of Unwanted Hair. <b>2009</b> , 239-252	1
509	Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. <b>2009</b> , 161, 411-8	30
508	Vernderungen an Haut und Haaren bei internistischen Erkrankungen. <b>2009</b> , 7, 9-16	
507	The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. <b>2009</b> , 279, 321-7	24
506	Interobserver variability of modified Ferriman-Gallwey hirsutism score in a Turkish population. <b>2009</b> , 279, 473-9	35
505	The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome. <b>2009</b> , 280, 263-9	8
504	Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. <b>2009</b> , 116, 1633-9	80
503	Hirsutism in young women. <b>2009</b> , 11, 101-107	2
502	A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. <b>2009</b> , 32, 37-40	13

501	Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). <b>2009</b> , 16, 938-46	5
500	The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function. <b>2009</b> , 91, 450-5	39
499	Inappropriate gonadotropin secretion in polycystic ovary syndrome. <b>2009</b> , 91, 1168-74	35
498	Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. <b>2009</b> , 91, 1848-52	48
497	The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. <b>2009</b> , 91, 456-88	1268
496	Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adolescents and young adults with polycystic ovary syndrome. <b>2009</b> , 22, 91-5	4
495	Doppler analysis of uterine perfusion and ovarian stromal blood flow in polycystic ovary syndrome. <b>2009</b> , 105, 154-7	17
494	Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. <b>2009</b> , 25, 508-13	53
493	Polycystic Ovary Syndrome and Hyperandrogenic States. <b>2009</b> , 489-516	2
492	Hepatotoxicity during low-dose flutamide treatment for hirsutism. <b>2009</b> , 25, 419-22	13
491	Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. <b>2009</b> , 25, 427-34	30
490	Diagnóstico del Síndrome de Ovario Poliquístico: nuevos fenotipos, nuevas incógnitas. <b>2009</b> , 137,	1
489	A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles. <b>2010</b> , 282, 199-205	27
488	Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. <b>2010</b> , 59, 575-80	53
487	Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. <b>2010</b> , 49, 775-9	16
486	Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). <b>2010</b> , 72, 26-31	60
485	Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. <b>2010</b> , 163, 139-47	17
484	Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. <b>2010</b> , 70, 1-7	19

483	Nonclassic congenital adrenal hyperplasia. <b>2010</b> , 2010, 625105	33
482	Long-Term Gynecological Outcomes in Women with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. <b>2010</b> , 2010, 784297	3
481	Prevalence of polycystic ovary syndrome and related disorders in mexican women. <b>2010</b> , 69, 274-80	86
480	Endocrinology of hirsutism. <b>2010</b> , 2, 30-5	13
479	Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role?. <b>2010</b> , 26, 39-46	29
478	Hirsutism: investigation and management. <b>2010</b> , 5, 189-195	3
477	The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperandrogenism. <b>2010</b> , 26, 139-43	18
476	Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. <b>2010</b> , 95, 789-99	44
475	Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?. <b>2010</b> , 95, 810-9	92
474	Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. <b>2010</b> , 25, 450-6	122
473	Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. <b>2010</b> , 70, 554-60	8
472	Diagnosis and management of hirsutism. <b>2010</b> , 1205, 166-74	34
471	Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. <b>2010</b> , 89, 199-204	54
470	Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. <b>2010</b> , 8, 142	33
469	Proteomic profiles in hyperandrogenic syndromes. <b>2010</b> , 33, 156-64	18
468	The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. <b>2010</b> , 25, 544-51	1082
467	Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. <b>2010</b> , 95, 5305-13	151
466	Visually scoring hirsutism. <b>2010</b> , 16, 51-64	198

465	Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. <b>2010</b> , 93, 880-4	47
464	Estrogen receptor beta gene +1730 G/A polymorphism in women with polycystic ovary syndrome. <b>2010</b> , 93, 1942-7	23
463	Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. <b>2010</b> , 93, 1938-41	89
462	Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. <b>2010</b> , 94, 255-60.e1-2	6
461	High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. <b>2010</b> , 94, 194-7	10
460	Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. <b>2010</b> , 94, 666-72	17
459	Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. <b>2010</b> , 94, 1451-1456	45
458	The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. <b>2010</b> , 94, 684-9	72
457	Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. <b>2010</b> , 94, 2197-201	118
456	Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. <b>2010</b> , 94, 2493-6	62
455	Hirsutism scoring in polycystic ovary syndrome: concordance between clinicians' and patients' self-scoring. <b>2010</b> , 94, 2815-6	5
454	A variant in the fibrillin-3 gene is associated with TGF- $\beta$ and inhibin B levels in women with polycystic ovary syndrome. <b>2010</b> , 94, 2916-9	43
453	Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor- $\alpha$ . <b>2010</b> , 95, 935-42	36
452	Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. <b>2010</b> , 26, 161-6	28
451	Cutaneous Manifestations of Endocrine Disease. <b>2011</b> , 172.1-172.31	
450	Handbook of hair in health and disease. <b>2011</b> ,	5
449	A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. <b>2011</b> , 84, 508-11	9
448	Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. <b>2011</b> , 95, 1849-52	45

447	The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. <b>2011</b> , 95, 1059-66.e1-7	88
446	Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. <b>2011</b> , 96, 246-50	48
445	Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. <b>2011</b> , 96, 224-229.e2	22
444	Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. <b>2011</b> , 95, 2595-8.e1-6	34
443	Defining hirsutism in Chinese women: a cross-sectional study. <b>2011</b> , 96, 792-6	80
442	Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism?. <b>2011</b> , 96, 1266-70.e1	35
441	Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. <b>2011</b> , 96, 1384-1390.e4	58
440	Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women. <b>2011</b> , 154, 167-71	28
439	Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age. <b>2011</b> , 154, 187-91	16
438	Brachial artery conductance during reactive hyperemia is increased in women with polycystic ovary syndrome. <b>2011</b> , 155, 49-53	8
437	Association of genetic variants in the two isoforms of 5 $\alpha$ -reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. <b>2011</b> , 157, 175-9	23
436	Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. <b>2011</b> , 159, 127-31	27
435	Congenital adrenal hyperplasia. <b>2011</b> , 24, 116-26	49
434	A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence. <b>2011</b> , 55, 590-8	18
433	Polycystic ovary syndrome: a dermatologic approach. <b>2011</b> , 86, 111-9	19
432	A patient with diabetes and breast cancer in whom virilization was caused by a testosterone-producing mature cystic teratoma containing a Brenner tumor. <b>2011</b> , 341, 74-7	7
431	Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. <b>2011</b> , 37, 1020-6	44
430	An overview of unwanted female hair. <b>2011</b> , 165 Suppl 3, 19-23	17

429	The lack of association between polycystic ovary syndrome and metabolic syndrome: Iranian PCOS prevalence study. <b>2011</b> , 75, 692-7	26
428	Association of polycystic ovarian syndrome with human leukocyte antigen polymorphism in Korean women. <b>2011</b> , 119, 618-25	4
427	Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. <b>2011</b> , 36, 1470-9	42
426	Ovarian morphology and endocrine function in polycystic ovary syndrome. <b>2011</b> , 284, 1443-8	17
425	The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. <b>2011</b> , 9, 144	34
424	The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. <b>2011</b> , 9, 39	161
423	Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. <b>2011</b> , 119, 451-5	38
422	Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. <b>2011</b> , 165, 789-96	43
421	Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. <b>2011</b> , 26, 214-20	45
420	The Optimal Number of Ovarian Punctures to Be Applied During Laparoscopic Ovarian Diathermy in Women with Polycystic Ovarian Syndrome. <b>2011</b> , 27, 217-224	3
419	Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of Turkey. <b>2011</b> , 39, 1529-35	5
418	Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial. <b>2011</b> , 300, E37-45	115
417	Polikistik over sendromu ve hirsutizm. <b>2011</b> , 46, 97-102	0
416	Uterine morphology and peristalsis in women with polycystic ovary syndrome. <b>2012</b> , 53, 1195-201	19
415	Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy. <b>2012</b> , 15, 101-5	4
414	A study on the clinical and hormonal profile of patients with hirsutism. <b>2012</b> , 3, 88-91	2
413	Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. <b>2012</b> , 23, 177-83	15
412	A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. <b>2012</b> , 166, 99-105	81



411	Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. <b>2012</b> , 27, 1481-8	31
410	Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. <b>2012</b> , 19, 383-90	36
409	Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia. <b>2012</b> , 167, 499-505	22
408	High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. <b>2012</b> , 28, 259-63	18
407	Epilepsi Tedavisi Alan Kadın Hastalarda Hipotalamo-Pituiter-Gonadal Aksiyon Değerlendirilmesi. <b>2012</b> , 49, 133-138	
406	Nonclassic congenital adrenal hyperplasia. <b>2012</b> , 19, 151-8	23
405	Anti-Müllerian hormone in women with polycystic ovary syndrome. <b>2012</b> , 55, 315	5
404	Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. <b>2012</b> , 119, 1151-6	5
403	Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. <b>2012</b> , 27, 1209-16	60
402	A 20-year follow-up of young women with polycystic ovary syndrome. <b>2012</b> , 119, 263-9	72
401	Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <b>2012</b> , 344, 363-73	23
400	Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. <b>2012</b> , 59, 781-90	43
399	Evaluation of various insulin sensitivity indices in lean idiopathic hirsutism patients. <b>2012</b> , 59, 291-6	9
398	Management of postmenopausal virilization. <b>2012</b> , 97, 2584-8	48
397	Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. <b>2012</b> , 163, 165-9	25
396	Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. <b>2012</b> , 97, 2039-49	323
395	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. <b>2012</b> , 18, 146-70	281
394	Does hyperandrogenism have an effect on hearing loss in patients with polycystic ovary syndrome?. <b>2012</b> , 39, 365-8	6

393	The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. <b>2012</b> , 33, 470-81	53
392	Association of IL-18 genotype with impaired glucose regulation in Korean women with polycystic ovary syndrome. <b>2012</b> , 161, 51-5	10
391	Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome. <b>2012</b> , 504, 133-9	14
390	Hiperandrogenismo y síndrome de ovario poliquístico. <b>2012</b> , 11, 895-903	
389	Mujer de 53 años con incidentaloma suprarrenal. <b>2012</b> , 11, 923.e1-923.e3	
388	Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor- $\beta$ levels in non-obese women with polycystic ovary syndrome. <b>2012</b> , 77, 1352-8	26
387	Hormones sexuelles. <b>2012</b> , 19-33	
386	[Insulin resistance in women with polycystic ovary syndrome: relationship with anthropometric and biochemical variables]. <b>2012</b> , 34, 74-9	8
385	[The importance of oral glucose tolerance test in diagnosis of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome]. <b>2012</b> , 34, 128-32	
384	Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism. <b>2012</b> , 42, 86-94	25
383	The new American Journal of Obstetrics and Gynecology, 5 years later: looking back and moving forward. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 206, 364-73	6.4 25
382	Factors affecting the degree of hirsutism in patients with polycystic ovary syndrome. <b>2012</b> , 285, 767-70	10
381	miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. <b>2013</b> , 62, 2278-86	177
380	Congenital adrenal hyperplasia pearls you should know--globally. <b>2013</b> , 26, 295	1
379	Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome. <b>2013</b> , 99, 599-604	11
378	Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <b>2013</b> , 98, 4565-92	1000
377	Acne severity and the Global Acne Grading System in polycystic ovary syndrome. <b>2013</b> , 123, 33-6	18
376	The Swedish version of the multidimensional scale of perceived social support (MSPSS)--a psychometric evaluation study in women with hirsutism and nursing students. <b>2013</b> , 11, 168	48

375	Ovulatory effects of flutamide in the polycystic ovary syndrome. <b>2013</b> , 29, 391-5	33
374	The lack of association between idiopathic hirsutism and metabolic disturbances: Iranian PCOS Prevalence Study. <b>2013</b> , 29, 821-5	7
373	Different phenotypes of polycystic ovary syndrome in Turkish women: clinical and endocrine characteristics. <b>2013</b> , 29, 931-5	16
372	Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. <b>2013</b> , 14, 42-9	40
371	Apolipoprotein B/apolipoprotein A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. <b>2013</b> , 39, 203-9	21
370	Prevalence of hyperprolactinaemia in female premenopausal blood donors. <b>2013</b> , 79, 545-9	10
369	Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. <b>2013</b> , 25, 127-32	38
368	Evaluation and treatment of hirsutism. <b>2013</b> , 10, 138-145	
367	Efficacy of omega-3 in the treatment of polycystic ovary syndrome. <b>2013</b> , 33, 289-91	35
366	How to diagnose and treat medically women with excessive hair. <b>2013</b> , 31, 57-65	15
365	Prevalence of polycystic ovary syndrome in women in China: a large community-based study. <b>2013</b> , 28, 2562-9	223
364	Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. <b>2013</b> , 28, 538-44	76
363	Interventions for hirsutism excluding laser and photoepilation therapy. <b>2013</b> ,	5
362	Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. <b>2013</b> , 98, 1602-11	89
361	Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors. <b>2013</b> , 28, 2245-52	39
360	Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial. <b>2013</b> , 19, 740-5	32
359	Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. <b>2013</b> , 98, 1641-50	30
358	Dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility. <b>2013</b> , 109, 2190-8	19

357	Low plasma atrial natriuretic peptide: a new piece in the puzzle of polycystic ovary syndrome. <b>2013</b> , 98, 4882-9	15
356	Idiopathic hirsutism and insulin resistance. <b>2013</b> , 2013, 593197	9
355	Clinical characteristics of polycystic ovary syndrome in Indian women. <b>2013</b> , 17, 138-45	49
354	Health-related quality of life, depression and anxiety correlate with the degree of hirsutism. <b>2013</b> , 227, 278-84	39
353	The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. <b>2013</b> , 168, 871-7	12
352	Routine screening for Cushing's syndrome is not required in patients presenting with hirsutism. <b>2013</b> , 168, 379-84	7
351	Evaluation of only the chin or lower abdomen for predicting hirsutism. <b>2013</b> , 17, 896-8	5
350	Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. <b>2013</b> , 98, 3058-67	41
349	[Contribution of hyperandrogenism to the development of metabolic syndrome in obese women with polycystic ovary syndrome]. <b>2013</b> , 35, 562-8	2
348	[Clinical manifestations, biochemical, ultrasonographic and metabolic of polycystic ovary syndrome in adolescents]. <b>2013</b> , 35, 249-54	10
347	Arterial hypertension and metabolic profile in patients with polycystic ovary syndrome. <b>2013</b> , 35, 21-6	7
346	The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). <b>2014</b> , 15, 70-83	13
345	Polycystic ovary syndrome: implications of metabolic dysfunction. <b>2014</b> , 41, 106-10	4
344	FTO Gene Variants Are Associated with PCOS Susceptibility and Hyperandrogenemia in Young Korean Women. <b>2014</b> , 38, 302-10	18
343	Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome. <b>2015</b> , 14, 101-8	16
342	Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. <b>2014</b> , 170, R75-90	26
341	Hypoxanthine Guanine Phosphoribosyl Transferase Is the Most Stable Reference Gene for Gene Expression Analysis by Quantitative PCR in Peripheral Blood Mononuclear Cells from Women with the Polycystic Ovary Syndrome. <b>2014</b> , 33, 356-363	1
340	Does polycystic ovary syndrome itself have additional effect on apelin levels?. <b>2014</b> , 2014, 536896	5

339	Prevalence of nonclassic congenital adrenal hyperplasia in Turkish children presenting with premature pubarche, hirsutism, or oligomenorrhoea. <b>2014</b> , 2014, 768506	11
338	Endocrine check-up in adolescents and indications for referral: A guide for health care providers. <b>2014</b> , 18, S26-38	5
337	Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. <b>2014</b> , 81, 93-9	27
336	Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome. <b>2014</b> , 29, 2764-72	17
335	Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross-sectional study. <b>2014</b> , 14, 76	27
334	Social support: an important factor for quality of life in women with hirsutism. <b>2014</b> , 12, 183	13
333	Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. <b>2014</b> , 77, 217-23	27
332	Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. <b>2014</b> , 101, 1732-9.e1-2	18
331	Lipid accumulation product and insulin resistance in Iranian PCOS prevalence study. <b>2014</b> , 81, 52-7	26
330	In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. <b>2014</b> , 24, 132-9	30
329	Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. <b>2014</b> , 47, 625-30	32
328	The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. <b>2014</b> , 29, 791-801	162
327	Global clinical response in Cushing's syndrome patients treated with mifepristone. <b>2014</b> , 80, 562-9	29
326	The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial. <b>2014</b> , 101, 258-269.e8	42
325	Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles. <b>2014</b> , 29, 2536-43	32
324	Tissue-specific dysregulation of 11 $\beta$ hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. <b>2014</b> , 171, 47-57	29
323	Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. <b>2014</b> , 170, 401-9	15
322	Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. <b>2014</b> , 180, 56-60	25

321	Live birth after fresh embryo transfer vs elective embryo cryopreservation/frozen embryo transfer in women with polycystic ovary syndrome undergoing IVF (FreFro-PCOS): study protocol for a multicenter, prospective, randomized controlled clinical trial. <b>2014</b> , 15, 154	28
320	Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. <b>2014</b> , 177, 121-5	6
319	Fertility outcome in male and female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <b>2014</b> , 19, 89-95	2
318	May AMH levels distinguish LOCAH from PCOS among hirsute women?. <b>2014</b> , 178, 183-7	3
317	Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate. <b>2014</b> , 101, 1747-56.e1-3	25
316	Evidence-Based Treatment of Hirsutism. <b>2014</b> , 498-503	
315	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME—PART 1. <b>2015</b> , 21, 1291-300	250
314	Preparation and clinical evaluation of Finastride gel in the treatment of idiopathic Hirsutism. <b>2015</b> , 4, 12-8	2
313	Valutazione e monitoraggio dell'irsutismo con metodi obiettivi: difficoltà e prospettive. <b>2015</b> , 16, 110-115	
312	Hirsutism: managing the basics. 1-10	
311	Interventions for hirsutism (excluding laser and photoepilation therapy alone). <b>2015</b> , CD010334	16
310	Psychological aspects of hyperandrogenic states in late adolescent and young women. <b>2015</b> , 83, 872-8	22
309	Comparison of Dietary Intake between Polycystic Ovary Syndrome Women and Controls. <b>2016</b> , 8, 54801	17
308	Birth weight and polycystic ovary syndrome in adult life: is there a causal link?. <b>2015</b> , 10, e0122050	11
307	Pathway Analysis Based on a Genome-Wide Association Study of Polycystic Ovary Syndrome. <b>2015</b> , 10, e0136609	27
306	Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study. <b>2015</b> , 10, e0137609	31
305	A simplified questionnaire for self-assessment of hirsutism in population-based studies. <b>2015</b> , 172, 451-9	1
304	Determining clinical and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal hyperplasia. <b>2015</b> , 173, 175-84	22

303	Endometrial preparation protocol of the frozen-thawed embryo transfer in patients with polycystic ovary syndrome. <b>2015</b> , 291, 201-11	28
302	Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. <b>2015</b> , 31, 396-400	18
301	Adrenal androgen excess and body mass index in polycystic ovary syndrome. <b>2015</b> , 100, 942-50	39
300	Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial. <b>2015</b> , 41, 287-97	9
299	Is idiopathic hirsutism (IH) really idiopathic? mRNA expressions of skin steroidogenic enzymes in women with IH. <b>2015</b> , 173, 447-54	4
298	The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome. <b>2015</b> , 30, 1927-33	37
297	Evidence-based approach to cutaneous hyperandrogenism in women. <b>2015</b> , 73, 672-90	31
296	Optimal management of polycystic ovary syndrome in adolescence. <b>2015</b> , 100, 1076-83	13
295	A comprehensive approach in diagnosing the polycystic ovary syndrome. <b>2015</b> , 11, 501-12	8
294	Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas. <b>2015</b> , 47, 652-5	1
293	Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. <b>2015</b> , 36, 487-525	401
292	A Case-Based Guide to Clinical Endocrinology. <b>2015</b> ,	
291	Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. <b>2015</b> , 173, 603-10	14
290	Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. <b>2015</b> , 173, 739-47	23
289	Endocrine and reproductive effects of polycystic ovarian syndrome. <b>2015</b> , 42, 55-65	16
288	Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. <b>2015</b> , 82, 885-91	50
287	Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. <b>2015</b> , 41, 402-10	10
286	Revised criteria for PCOS in WHO Group II anovulatory infertility - a revival of hypothalamic amenorrhoea?. <b>2015</b> , 82, 584-91	15

285	Relationship between pelvic floor muscle and hormone levels in polycystic ovary syndrome. <b>2016</b> , 35, 780-5	5
284	Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. <b>2016</b> , 175, 45-61	22
283	Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. <b>2016</b> , 42, 678-83	15
282	Vitamin D Status Relates to Reproductive Outcome in Women With Polycystic Ovary Syndrome: Secondary Analysis of a Multicenter Randomized Controlled Trial. <b>2016</b> , 101, 3027-35	51
281	Increased antimüllerian hormone levels and other reproductive endocrine changes in adult male relatives of women with polycystic ovary syndrome. <b>2016</b> , 106, 50-55	26
280	The impact of insulin resistance on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome. <b>2016</b> , 36, 893-896	12
279	The Effects of Soy Isoflavones on Metabolic Status of Patients With Polycystic Ovary Syndrome. <b>2016</b> , 101, 3386-94	34
278	Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. <b>2016</b> , 375, 523-33	377
277	Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology. <b>2016</b> , 54, 798-807	2
276	What does a diagnostic label of 'polycystic ovary syndrome' really mean in adolescence? A review of current practice recommendations. <b>2016</b> , 6, 1-18	11
275	Alterations in nasal mucociliary activity in polycystic ovary syndrome. <b>2016</b> , 207, 169-172	5
274	Health-related quality-of-life questionnaire for women with polycystic ovary syndrome: a Chinese translation and validation study. <b>2016</b> , 123, 1638-45	2
273	Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. <b>2016</b> , 101, 3288-96	21
272	Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome. <b>2016</b> , 44, 796-805	26
271	Cystatin C, a novel cardiometabolic risk marker in women with polycystic ovary syndrome. <b>2016</b> , 32, 457-9	1
270	Sexual Function and Depressive Symptoms in Young Women With Nonclassic Congenital Adrenal Hyperplasia. <b>2016</b> , 13, 34-9	8
269	Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. <b>2016</b> , 32, 276-80	18
268	Assessing new terminal body and facial hair growth during pregnancy: toward developing a simplified visual scoring system for hirsutism. <b>2016</b> , 105, 494-500	5



267	Cutaneous Findings and Systemic Associations in Women With Polycystic Ovary Syndrome. <b>2016</b> , 152, 391-8		44
266	Mass spectrometry methods measured androgen and estrogen concentrations during pregnancy and in newborns of mothers with polycystic ovary syndrome. <b>2016</b> , 174, 25-32		45
265	The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2016</b> , 172, 72-78		29
264	Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. <b>2016</b> , 293, 447-56		30
263	Selenium Supplementation and the Effects on Reproductive Outcomes, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome. <b>2016</b> , 48, 185-90		42
262	Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2016</b> , 170, 271-8		38
261	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. <b>2016</b> , 2275-2296.e6		2
260	Is the association between insulin resistance and diabetogenic haematopoietically expressed homeobox (HHEX) polymorphism (rs1111875) affected by polycystic ovary syndrome status?. <b>2017</b> , 29, 670-678		4
259	Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 216, 493.e1-493.e13	6.4	47
258	Is acne a sign of androgen excess disorder or not?. <b>2017</b> , 211, 21-25		18
257	The Effects of Omega-3 Fatty Acids Supplementation on Gene Expression Involved in the Insulin and Lipid Signaling Pathway in Patients with Polycystic Ovary Syndrome. <b>2017</b> , 49, 446-451		20
256	Practical Approach to the PCOS Patient. <b>2017</b> , 6, 11-20		
255	Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 189.e1-189.e8	6.4	38
254	The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Indices of Insulin Resistance and Hormonal Parameters in Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. <b>2017</b> , 125, 353-359		24
253	Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. <b>2017</b> , 177, 93-102		23
252	Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China. <b>2017</b> , 13, 1337-1342		6
251	Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. <b>2017</b> , 87, 194-200		16
250	The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. <b>2017</b> , 22, 172-182		9

249	Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study. <b>2017</b> , 33, 801-806	7
248	Assessment of the body composition of patients with polycystic ovary syndrome using dual-energy X-ray absorptiometry. <b>2017</b> , 136, 285-289	4
247	Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years. <b>2017</b> , 35, 331-339	4
246	Individualised gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: A prospective, observational study. <b>2017</b> , 210, 76-82	3
245	No. 350-Hirsutism: Evaluation and Treatment. <b>2017</b> , 39, 1054-1068	4
244	Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. <b>2017</b> , 32, 2515-2521	43
243	Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. <b>2017</b> , 177, 399-408	16
242	Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. <b>2017</b> , 7, 5339	28
241	Effect of Preconception Impaired Glucose Tolerance on Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. <b>2017</b> , 102, 3822-3829	14
240	The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. <b>2017</b> , 49, 493-498	35
239	LATE-NIGHT SALIVARY CORTISOL IS UNALTERED IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS), IRRESPECTIVE OF DISEASE PHENOTYPE, AND IN OBESE WOMEN, IRRESPECTIVE OF THE PRESENCE OF PCOS. <b>2017</b> , 23, 1045-1052	3
238	Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study. <b>2017</b> , 102, 122-131	21
237	Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. <b>2017</b> , 40, 377-384	18
236	The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women. <b>2017</b> , 33, 160-163	19
235	The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome. <b>2017</b> , 439, 247-255	37
234	A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome. <b>2019</b> , 34, 108-114	3
233	N 350-Hirsutisme : Évaluation et traitement. <b>2017</b> , 39, 1069-1084	
232	Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. <b>2017</b> , 6, 248-255	22

231	The Contribution of New Areas to the Total Hirsutism Scores in Basrah Hirsute Women. <b>2017</b> , 5,	3
230	Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. <b>2018</b> , 103, 824-838	20
229	The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. <b>2018</b> , 18, 21	29
228	Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. <b>2018</b> , 103, 1233-1257	123
227	Serum irisin concentrations in lean adolescents with polycystic ovary syndrome. <b>2018</b> , 88, 585-591	4
226	Diagnostic Criteria for PCOS. <b>2018</b> , 11-21	
225	The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women. <b>2018</b> , 63, 242-248	10
224	New perspectives on the definition and management of polycystic ovary syndrome. <b>2018</b> , 41, 1123-1135	35
223	The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome. <b>2018</b> , 229, 41-47	28
222	The Influences of Chromium Supplementation on Glycemic Control, Markers of Cardio-Metabolic Risk, and Oxidative Stress in Infertile Polycystic ovary Syndrome Women Candidate for In vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2018</b> , 185, 48-55	14
221	Cardiotrophin-1 as a new metabolic biomarker in women with PCOS. <b>2018</b> , 34, 781-783	1
220	[Diffuse hypertrichosis revealing non-classical congenital adrenal hyperplasia]. <b>2018</b> , 145, 270-277	1
219	Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states. <b>2018</b> , 91, 31-40	6
218	Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. <b>2018</b> , 17, 511-517	12
217	The Effects of Selenium Supplementation on Gene Expression Related to Insulin and Lipid in Infertile Polycystic Ovary Syndrome Women Candidate for In Vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2018</b> , 183, 218-225	17
216	Sexual function in women with polycystic ovary syndrome and their hormonal and clinical correlations. <b>2018</b> , 30, 54-61	10
215	Prediction of age at menopause in women with polycystic ovary syndrome. <b>2018</b> , 21, 29-34	26
214	The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. <b>2018</b> , 126, 222-228	25

213	Controversies in Polycystic Ovary Syndrome. <b>2018</b> ,		
212	Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study. <b>2018</b> , 110, 1377-1386		26
211	The effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. <b>2018</b> , 1-9		11
210	The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome. <b>2018</b> , 238, 32-38		35
209	Association among depression, symptom experience, and quality of life in polycystic ovary syndrome. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 219, 279.e1-279.e7	6.4	25
208	Galectin-3 as a novel biomarker in women with PCOS. <b>2018</b> , 298, 821-825		2
207	Endometrial neoplasia in reproductive-aged Thai women with polycystic ovary syndrome. <b>2018</b> , 142, 170-175		2
206	Insulin resistance is associated with depression risk in polycystic ovary syndrome. <b>2018</b> , 110, 27-34		18
205	Elevated PAPP-A levels in lean patients with polycystic ovary syndrome. <b>2018</b> , 57, 394-398		2
204	Association between major dietary patterns and polycystic ovary syndrome: evidence from a case-control study. <b>2019</b> , 44, 52-58		8
203	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. <b>2019</b> , 194, 105445		13
202	Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. <b>2019</b> , 91, 553-560		10
201	Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill ( ): A Randomized Controlled Clinical Trial. <b>2019</b> , 25, 246-251		10
200	Polycystic Ovary Syndrome. <b>2019</b> , 55-67		0
199	FP728LOW LEAN TISSUE AND HIGH FAT TISSUE INDEX ARE ASSOCIATED WITH DECREASED QUALITY OF LIFE IN DIALYSIS PATIENTS. <b>2019</b> , 34,		
198	Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. <b>2019</b> , 45, 2330-2337		17
197	Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome?. <b>2019</b> , 19, 93		16
196	Endocrinology of Hirsutism: From Androgens to Androgen Excess Disorders. <b>2019</b> , 53, 108-119		7

195	Besonderheiten des Haarwuchses und -verlustes in der Pubertät <b>2019</b> , 167, 1142-1148	
194	Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. <b>2019</b> , 12, 5	37
193	Insulin resistance is associated with hirsutism in unselected reproductive-aged women. <b>2019</b> , 90, 586-591	3
192	Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization. <b>2019</b> , 3, 1087-1096	7
191	Sexual Function and Socio-Sexual Difficulties in Women with Polycystic Ovary Syndrome (PCOS). <b>2019</b> , 79, 498-509	7
190	Lasers for Hair Removal. <b>2019</b> , 273-287	1
189	Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome. <b>2019</b> , 10, 273	21
188	Serum Vitamin D Levels in Fertile and Infertile Women with Polycystic Ovary Syndrome. <b>2019</b> , 79, 510-516	6
187	How to Evaluate Acne in Reproductive-Age Women: An Epidemiological Study in Chinese Communities. <b>2019</b> , 2019, 6126808	3
186	Polycystic Ovary Syndrome and Insulin Physiology: An Observational Quantitative Serum Proteomics Study in Adolescent, Normal-Weight Females. <b>2019</b> , 13, e1800184	8
185	Hair disorders in patients with cancer. <b>2019</b> , 80, 1179-1196	30
184	Comprehensive genotyping of Turkish women with hirsutism. <b>2019</b> , 42, 1077-1087	2
183	Prevalence and characteristics of polycystic ovary syndrome in Brazilian women: protocol for a nation-wide case-control study. <b>2019</b> , 9, e029191	5
182	Cutaneous Manifestations of Endocrine Disease. <b>2019</b> , 1993-2009	
181	. <b>2019</b> ,	
180	The ratio of anterior anogenital distance to posterior anogenital distance: A novel-biomarker for polycystic ovary syndrome. <b>2019</b> , 82, 782-786	13
179	The diagnosis and treatment of PCOS in adolescents: an update. <b>2019</b> , 31, 562-569	26
178	Effect of body mass index on pregnancy outcomes with the freeze-all strategy in women with polycystic ovarian syndrome. <b>2019</b> , 112, 1172-1179	10

177	The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome. <b>2019</b> , 191, 54-60	17
176	Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. <b>2019</b> , 9, e024733	10
175	Top-cited articles in the Journal: a 'bibliometric' analysis. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 220, 12-25	6.4 12
174	Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. <b>2019</b> , 48, 335-339	6
173	Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome. <b>2019</b> , 111, 389-396	14
172	Polycystic Ovary Syndrome. <b>2019</b> , 415-435	
171	Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome. <b>2020</b> , 36, 143-147	1
170	Hyperandrogenemia is Common in Asymptomatic Women and is Associated with Increased Metabolic Risk. <b>2020</b> , 28, 106-113	1
169	Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients. <b>2020</b> , 11, 575337	8
168	The risk of chronic kidney disease among women with polycystic ovary syndrome: A long-term population-based cohort study. <b>2020</b> , 93, 590-597	0
167	Controversies in the diagnosis of polycystic ovary syndrome. <b>2020</b> , 14, 2633494120913032	6
166	Haarwuchs und -verlust in der Pubertät. <b>2020</b> , 12, 34-41	
165	Endocrine Pathophysiology. <b>2020</b> ,	
164	The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome. <b>2020</b> , 41, 734-742	1
163	Hormonal Effects on Hair Follicles. <b>2020</b> , 21,	26
162	Five variants of the superoxide dismutase genes in Turkish women with polycystic ovary syndrome. <b>2020</b> , 54, 467-476	0
161	Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?. <b>2020</b> , 84, 102099	2
160	The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial. <b>2020</b> , 11, 590392	0

159	Cell Glucose Sensitivity determines hyperglycaemia in Polycystic Ovary Syndrome. <b>2020</b> , 3, 35-41	
158	Polycystic ovary syndrome and endothelial dysfunction: A potential role for soluble lectin-like oxidized low density lipoprotein receptor-1. <b>2020</b> , 20, 396-401	5
157	The relationship between obstructive sleep apnoea and quality of life in women with polycystic ovary syndrome: a cross-sectional study. <b>2020</b> , 11, 2042018820906689	7
156	Clinical effects of Shou-Wu Jiang-Qi Decoction combined acupuncture on the treatment of Polycystic Ovarian Syndrome with kidney deficiency, phlegm and blood stasisness: Study protocol clinical trial (SPIRIT Compliant). <b>2020</b> , 99, e19045	6
155	Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: A cross-sectional study. <b>2020</b> , 248, 137-143	3
154	Anti-Müllerian Hormone and Ovarian Morphology in Women With Hypothalamic Hypogonadism. <b>2020</b> , 105,	12
153	Adjusting anti-Müllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome. <b>2020</b> , 113, 876-884.e2	1
152	Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations. <b>2020</b> , 105,	8
151	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <b>2021</b> , 24, 104-115	10
150	Overlap of autism and conditions associated with atypical sex hormone levels or response: A systematic review and meta-analysis. <b>2021</b> , 80, 101693	4
149	A bibliometric analysis of obstetrics and gynecology articles with highest relative citation ratios, 1980 to 2019. <b>2021</b> , 3, 100293	6
148	Influence of ethnicity on different aspects of polycystic ovary syndrome: a systematic review. <b>2021</b> , 42, 799-818	2
147	Serum kisspeptin levels correlated with anti-müllerian hormone levels in women with and without polycystic ovarian syndrome. <b>2021</b> , 37, 462-466	3
146	The Role of Probiotics and Synbiotics on Hirsutism. <b>2021</b> , 7, 10	1
145	Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome. <b>2021</b> , 1, 54	1
144	Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome. <b>2021</b> , 1, 54	
143	POLİESTER OVER SENDROMUNDA (PKOS) ENDOTELYAL DİSFONKSİYONUN ERKEN SERUM BELİRTECİSİ ENDOCAN.	
142	Racial and Ethnic Differences in Metabolic Disease in Adolescents With Obesity and Polycystic Ovary Syndrome. <b>2021</b> , 5, bvab008	3

141	Comparative study of the clinico-trichoscopic response to treatment of hirsutism with long pulsed (1064 nm) Nd:YAG laser in idiopathic hirsutism and polycystic ovarian syndrome patients. <b>2021</b> , 1	1
140	Evaluation of endometrial immune status of polycystic ovary syndrome. <b>2021</b> , 144, 103282	5
139	Leydigcelhyperplasie: een zeldzame oorzaak van hyperandrogenisme bij een menopauzale vrouw.	
138	Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study. <b>2021</b> , 36, 1611-1620	4
137	Wet-cupping on calf muscles in polycystic ovary syndrome: a quasi-experimental study. <b>2021</b> ,	
136	Postmenopausal hyperandrogenism. <b>2021</b> , 1-9	2
135	Diagnosis delayed: health profile differences between women with undiagnosed polycystic ovary syndrome and those with a clinical diagnosis by age 35 years. <b>2021</b> , 36, 2275-2284	2
134	Polycystic ovary syndrome and (pre)osteoarthritis: assessing the link between hyperandrogenism in young women and cartilage oligomeric matrix protein as a marker of cartilage breakdown. <b>2021</b> , 40, 4217-4223	3
133	Effects of Melatonin and/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. <b>2021</b> , 1	4
132	Clinico-investigative attributes of 122 patients with hirsutism: A 5-year retrospective study from India. <b>2021</b> , 7, 237-242	1
131	Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome. <b>2021</b> , 44, 2725-2733	2
130	Addressing important knowledge gaps about the disease burden of hirsutism. <b>2021</b> , 7, 243-245	
129	The Need to Reassess the Diagnosis of Polycystic Ovary Syndrome (PCOS): A Review of Diagnostic Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. <b>2021</b> , 39, 71-77	1
128	Physical and Sociodemographic Features Associated With Quality of Life Among Transgender Women and Men Using Gender-Affirming Hormone Therapy. <b>2021</b> , 12, 621075	2
127	Evaluation of the Prevalence, Regional Phenotypic Variation, Comorbidities, Risk Factors, and Variations in Response to Different Therapeutic Modalities Among Indian Women: Proposal for the Indian Council of Medical Research-Polycystic Ovary Syndrome (ICMR-PCOS) Study. <b>2021</b> , 10, e23437	0
126	Update on polycystic ovary syndrome. <b>2021</b> , 48, 194-197	1
125	Serum sclerostin level and its relation to subclinical atherosclerosis in the polycystic ovary syndrome phenotypes: A prospective controlled study. <b>2021</b> , 18, 167-174	
124	Prevalence of Hirsutism Among Reproductive-Aged African American Women. <b>2021</b> , 30, 1580-1587	2



123	Cutaneous manifestation of polycystic ovary syndrome. <b>2021</b> , 13, 8799	2
122	Plasminogenactivator inhibitor-1 polymorphism and risk of polycystic ovary syndrome in Turkish women. <b>2021</b> , 30, 100959	
121	Androgen excess in women. <b>2022</b> , 810-823.e3	
120	Clinical Features of the Polycystic Ovary Syndrome. <b>2006</b> , 155-167	1
119	Clinical and Hormonal Evaluation of Androgen Excess. <b>2006</b> , 365-375	1
118	Hair Growth Assessment Techniques. <b>2008</b> , 125-157	15
117	Hyperandrogenism in Women. <b>1997</b> , 517-584	1
116	Hirsutism and Hypertrichosis. <b>2015</b> , 385-396	2
115	Pubertal Disorders: Psychology and Clinical Management. <b>1991</b> , 20, 211-230	18
114	Evaluation and Therapy of Polycystic Ovarian Syndrome. <b>1988</b> , 17, 785-813	10
113	The effects of vitamin D and evening primrose oil co-supplementation on lipid profiles and biomarkers of oxidative stress in vitamin D-deficient women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. <b>2018</b> , 43, 1-10	14
112	Polycystic ovary syndrome: clinical perspectives and management. <b>1999</b> , 54, 403-13	49
111	Comparison of the Association of Excess Weight on Health Related Quality of Life of Women with Polycystic Ovary Syndrome: An Age- and BMI-Matched Case Control Study. <b>2016</b> , 11, e0162911	8
110	Comparison of uterine and ovarian stromal blood flow in patients with polycystic ovarian syndrome. <b>2019</b> , 8, 50-56	3
109	[Difficulties and pitfalls in the diagnosis of polycystic ovary syndrome]. <b>2011</b> , 55, 6-15	6
108	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center. <b>2020</b> , 64, 235-242	6
107	Healthy eating index in women with polycystic ovary syndrome: A case-control study. <b>2017</b> , 15, 575-582	3
106	The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women. <b>2019</b> , 34, 374-381	8

105	Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report. <b>2013</b> , 15,	1
104	Hirsutism: clinico-investigative profile of 50 Indian patients. <b>2008</b> , 53, 111-4	11
103	Autistic Trait, Empathy, and Attention-Deficit/Hyperactivity Symptoms in Women with Idiopathic Hirsutism. <b>2015</b> , 7, 113-8	2
102	Modified Ferriman-Gallwey Score in Hirsutism and its Association with Metabolic Syndrome. <b>2017</b> , 9, 7-13	20
101	Reproductive disturbances among Saudi adolescent girls and young women with type 1 diabetes mellitus. <b>2017</b> , 8, 475-483	3
100	Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome. <b>2016</b> , 8, 55-60	5
99	Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. <b>2016</b> , 13, 1-6	5
98	Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. <b>2014</b> , 41, 86-91	25
97	Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome. <b>2014</b> , 12, e18642	8
96	Metabolic and hormonal assessment of adolescent and young adult women with prior premature adrenarche. <b>2019</b> , 74, e836	4
95	Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. <b>2016</b> , 30, 197-202	13
94	The effects of coenzyme Q10 supplementation on metabolic profiles and parameters of mental health in women with polycystic ovary syndrome. <b>2021</b> , 1-5	3
93	Hair Metrology. <b>2004</b> , 255-270	
92	The genetics of polycystic ovary syndrome. <b>2005</b> , 74-91	
91	Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome. <b>2010</b> , 2386-2406	
90	Polycystic Ovary Syndrome. <b>2013</b> , 113-123	
89	Hirsutism and Virilization. <b>2014</b> , 145-157	
88	Androgenisierungserscheinungen bei der Frau. <b>1987</b> , 563-611	4

- 87 Hirsutism. **1988**, 371-391
- 86 Androgenisierungserscheinungen bei der Frau. **1994**, 589-665 1
- 85 Getting Pregnant with PCOS. **2015**, 317-326
- 84 The Frequency of Various Phenotypes of Polycystic Ovarian Syndrome in Adolescents, Based on Rotterdam Criteria. **2015**, 2,
- 83 The Relationship Between Acne and Other Hyperandrogenism Signs. **2016**, 3, 1
- 82 Evaluation and Management of Hirsutism in Postmenopausal Women. **2017**, 209-219 1
- 81 Polycystic Ovary Syndrome. **2017**, 123-137 1
- 80 Hirsutism. **2017**, 1443-1447
- 79 Prevalence of Polycystic Ovary Syndrome in Nigerian Women with Infertility: A Prospective Study of the Three Assessment Criteria. **2018**, 08, 1109-1120 1
- 78 Heavy Menstrual Bleeding in Adolescent Girls. **2020**, 49, e163-e169 3
- 77 Hydroclathrus clathratus as anti-damaging agent against lung injury in male albino rats. **2020**, 9,
- 76 Evaluation of the Prevalence, Regional Phenotypic Variation, Comorbidities, Risk Factors, and Variations in Response to Different Therapeutic Modalities Among Indian Women: Proposal for the Indian Council of Medical Research Polycystic Ovary Syndrome (ICMR PCOS) Study (Preprint).
- 75 Irregular Menses. **2021**, 95-100
- 74 Disorders of Sex Development. **2021**, 271-274
- 73 Laboratory Evaluation in Adolescence. **1983**, 211-226
- 72 Literaturverzeichnis. **2020**, 247-254
- 71 Impact of Subclinical Hypothyroidism on Reproductive and Metabolic Parameters in Polycystic Ovary Syndrome - A Cross-sectional Study from Bangladesh. **2020**, 16, 156-160 2
- 70 Polycystic Ovary Syndrome and Obstructive Sleep Apnea. **2020**, 177-202

69	Reproductive Organ Signs. <b>2020</b> , 127-149	
68	Divergences in Clinical, Anthropometric, Metabolic, and Hormonal Parameters among Different Phenotypes of Polycystic Ovary Syndrome Presenting at Endocrinology Outpatient Departments: A Multicenter Study from Bangladesh. <b>2020</b> , 13, 277-284	0
67	Prevalence of thyroid dysfunction and thyroid autoimmunity in polycystic ovary syndrome: A multicenter study from Bangladesh. <b>2020</b> , 17, 76	0
66	Polycystic Ovary Syndrome. <b>2020</b> , 83-97	0
65	Prevalence of Cutaneous Disorders in Patients with Polycystic Ovary Syndrome. <b>2020</b> , 10, 1246-1264	
64	Systematic review of finasteride effect in women with hirsutism. <b>2021</b> , 67, 1043-1049	
63	Polycystic Ovary Syndrome and Obstructive Sleep Apnea. <b>2006</b> , 125-144	
62	Polycystic Ovary Syndrome. <b>2007</b> , 219-242	
61	Acne, Hirsutism, and Other Signs of Increased Androgens. <b>2021</b> , 85-94	
60	Polycystic Ovarian Disease. <b>1987</b> , 14, 931-953	3
59	Hirsutism. <b>1985</b> , 12, 649-674	2
58	Hirsutism: common clinical problem or index of serious disease?. <b>2004</b> , 6, 56	3
57	Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. <b>2011</b> , 16, 999-1005	12
56	The Prevalence of Polycystic Ovary Syndrome (PCOS) in High School Students in Rasht in 2009 According to NIH Criteria. <b>2011</b> , 4, 156-9	13
55	Healthy eating index in women with polycystic ovary syndrome: A case-control study. <b>2017</b> , 15, 575-582	4
54	Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. <b>2021</b> , 21, 31	
53	Irsutismo: focus su patogenesi e diagnosi. <b>2021</b> , 22, 544	
52	Impact of Polycystic Ovary Syndrome on Silent Coronary Artery Disease and Cardiovascular Events; A Long-term Population-based Cohort Study. <b>2021</b> ,	0

51	Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. <b>2020</b> , 21, 1-1	1
50	Clinical, Laboratory, and Radiological Diagnosis of Hyperandrogenism. <b>2022</b> , 45-52	
49	Associations Between Sex Hormone Levels and Autistic Traits in Infertile Patients With Polycystic Ovary Syndrome and Their Offspring.. <b>2021</b> , 12, 789395	0
48	Characterizing Dermatological Conditions in the Transgender Population: A Cross-Sectional Study.	0
47	Hirsutism and Virilization. <b>2022</b> , 115-126	
46	Association of antimüllerian hormone with polycystic ovarian syndrome phenotypes and pregnancy outcomes of in vitro fertilization cycles with fresh embryo transfer.. <b>2022</b> , 22, 171	0
45	The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.. <b>2022</b> , 13, 825528	0
44	Analysis of 2-Arachidonoylglycerol Levels in Polycystic Ovary Syndrome in the Context of Hormonal and Metabolic Alterations and Across the Classical Phenotypes.. <b>2022</b> ,	0
43	Differences in hormonal levels between heterozygous pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia.. <b>2022</b> ,	
42	Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Female Pattern Hair Loss. <b>2022</b> , 205-231	
41	Image_1.tif. <b>2020</b> ,	
40	Table_1.docx. <b>2020</b> ,	
39	Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism. <b>2013</b> , 36, 50-4	1
38	Care of the Child with a Pediatric Endocrine Disorder. <b>2022</b> , 413-460	
37	Etiology and management of amenorrhea in adolescent and young adult women.. <b>2022</b> , 101184	0
36	Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. <b>2022</b> , 22,	1
35	Contraception oestroprogestative et spironolactone dans le hirsutisme : efficacité et impact sur la qualité de vie. <b>2022</b> ,	
34	Evaluation of Pregnancy Complications in Women with Polycystic Ovarian Syndrome Who Have Undergone In Vitro Fertilization (IVF). <b>2022</b> , 75, 279-285	

- 33 The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population. 13, 2
- 32 Regional variability of modified Ferriman-Gallwey scoring in premenopausal healthy women in Southern Turkey. 1-6 0
- 31 High Throughput Sequencing to Identify Monogenic Etiologies in a Preselected Polycystic Ovary Syndrome Cohort.
- 30 Early Clinical, Biochemical and Radiological Features in Obese and Non-Obese Young Women with Polycystic Ovarian Syndrome: A Comparative Study. 0
- 29 Metabolic status is not related to dietary acid load in polycystic ovary syndrome.
- 28 Hirsutism, Normal Androgens and Diagnosis of PCOS. **2022**, 12, 1922 2
- 27 Effects of probiotic supplementation on hormonal and clinical outcomes of women diagnosed with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled clinical trial. **2022**, 96, 105203
- 26 Development and validation of a prediction model for depression in adolescents with polycystic ovary syndrome: A study protocol. 13, 1
- 25 ADULT ACNE: ITS CLINICOEPIDEMIOLOGICAL FEATURES. **2022**, 21-23 0
- 24 Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). 0
- 23 Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important Than the Rotterdam Phenotype in Influencing the Metabolic Status. **2022**, 12, 2313 2
- 22 A triple-blind randomized controlled trial comparing combined letrozole and clomiphene versus only letrozole for ovulation induction in PCOS women. 0
- 21 Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years. **2022**, 11, 3255 0
- 20 Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. **2022**, 0
- 19 Regional Variation in Hormonal and Metabolic Parameters of White and Black Women With PCOS in the United States. 0
- 18 Evaluation of novel obesity- and lipid-related indices as predictors of abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. **2022**, 22, 0
- 17 Female sexual function in different phenotypes of polycystic ovarian syndrome: a comparative cross-sectional study. **2022**, 12, 0
- 16 Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI). 0

- 15 Relation Between Non-Alcoholic Fatty Pancreas and Clinical and Biochemical Parameters in Women with Polycystic Ovary Syndrome: A Multi-Centric Study. Volume 15, 8225-8233 ○
- 14 Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?. **2022**, 32, 490-493 ○
- 13 Congenital Adrenal Hyperplasia. **2023**, 1-2 ○
- 12 Comparison of image-based modified Ferriman-Gallway score evaluation with in-person evaluation: an alternative method for hirsutism diagnosis. ○
- 11 Comparison of physical activity levels and dietary habits between women with polycystic ovarian syndrome and healthy controls of reproductive age: A case-control study. ○
- 10 Hirsutism. **2016**, 1-5 ○
- 9 Prevalence of polycystic ovary syndrome under NIH criteria among the tenth-grade Chinese schoolgirls in Guangzhou area: a cross-sectional epidemiological survey. **2023**, 23, ○
- 8 Fifteen-minute consultation: Approach to the adolescent presenting with hirsutism. edpract-2022-324465 ○
- 7 Diagnostic Performance of Ovarian Morphology on Ultrasonography across Anovulatory Conditions Impact of Body Mass Index. **2023**, 13, 374 ○
- 6 Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers. ○
- 5 Improved 2 $\beta$ -Hydroxylation Efficiency of Steroids by CYP154C2 Using Structure-Guided Rational Design. **2023**, 89, ○
- 4 Current Guidelines for Diagnosing PCOS. **2023**, 13, 1113 ○
- 3 Polycystic Ovarian Syndrome. **2023**, 95-121 ○
- 2 Diagnostic criteria for polycystic ovary syndrome. **2024**, 61-74 ○
- 1 Serum metabolomics profiling by proton nuclear magnetic resonance spectroscopy reveals sexual dimorphism and masculinization of intermediate metabolism in women with polycystic ovary syndrome (PCOS). **2023**, 14, ○